2025-11-01から1ヶ月間の記事一覧
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.Chang JY, Lin SH, Dong W, et al. Lan…
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Tree AC, Hinder V, Chan …
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.van As N, Griffin C, Tree A, et al. N Engl J Med. 2024 Oct 17;391(15):1413-1425. DOI: 10.1056/NEJMoa2403365. PMID: 39413377; PMCID: PMC7616714. 【背景】・前立腺が…
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Widmark A, Gunnlaugsson A, Beckman L, et al. Lancet. 2019 Aug 3;394(1…
A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.Thakur V, Khosla D, Singh G, et al. J Gastrointest …
Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy.Bilski M, Noël G, Smółka K, et al. Sci Rep. 2025 Oct 30;15(1):38011. doi: 10.1038/s41598-025-21934-2. PMID: 41168285. 【概要】・WHO 2…
Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis.Hoosemans LJN, Panayotopoulos LF, van Kuijk SMJ, et al. J Neurooncol. 2025 Oct 24;176(1):42. doi: 10.1007/s11060-025-05299-0. PMID: 41134378; PMCID: …
